NCT06476899View on ClinicalTrials.gov

A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

March 26, 2026

Study Completion Date

December 26, 2026

Conditions

CLL/SLL

Interventions

DRUG

orelabrutinib

orelabrutinib tablets

DRUG

FCR/BR

FCR/BR

DRUG

BTK inhibitor

BTK inhibitor choose by physican

All Listed Sponsors

lead

Fei Li

OTHER